Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2

Status

Completed 5

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Stomach Neoplasms 3Pancreatic Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Oxaliplatin 1439Fluorouracil 1319Capecitabine 1114Gemcitabine 1057Leucovorin 939Bevacizumab 847Irinotecan 830Cisplatin 676Radiotherapy 560Cetuximab 482pembrolizumab 435Paclitaxel 401Drug Therapy 358Nivolumab 350130-nm albumin-bound paclitaxel 328Docetaxel 290Sorafenib 288S 1 (combination) 279Folfox protocol 266Albumin-Bound Paclitaxel 263Surgical Procedures, Operative 257lenvatinib 222sintilimab 218tislelizumab 214durvalumab 212regorafenib 209Magnetic Resonance Spectroscopy 205apatinib 204Radiosurgery 204Neoadjuvant Therapy 190

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
gastrin immunogen × Gastrointestinal × Clear all
NCT00020787 2020-08-03

Vaccine Therapy Plus Chemotherapy in Treating Patients With Metastatic or Locally Recurrent Stomach Cancer or Esophageal Cancer

Jonsson Comprehensive Cancer Center

Phase 3 Completed
8 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

NCT02521649 2015-08-13

Dose-ranging Study to Evaluate Antibody Response to G17DT in Patients With Gastric Cancer

Cancer Advances Inc.

Phase 2 Completed
52 enrolled
Gastrointestinal

Stomach Neoplasms

NCT02518529 2015-08-10

Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients

Cancer Advances Inc.

Phase 2 Completed
41 enrolled
Gastrointestinal

Stomach Neoplasms

NCT02518373 2015-08-07

CC5

Cancer Advances Inc.

Phase 2 Completed
22 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT00044031 2014-04-17

Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma

Cancer Advances Inc.

Phase 3 Completed
394 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡